ArticleAnalytical and bioanalytical chemistry2026
A systematic DoE approach for optimizing urinary LC-HRMS metabolomics: enhancing reliability in bladder cancer profiling.
Article in Analytical and bioanalytical chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Untargeted urinary metabolomics presents significant challenges in analytical reproducibility and biological interpretation, particularly in the context of clinical oncology. This study presents a systematically optimized liquid chromatography-high-resolution mass spectrometry (LC-HRMS) workflow for bladder cancer (BCa) biomarker discovery. To address variability in sample preparation, a two-stage design of experiments (DoE) approach was applied to systematically optimize key parameters affecting metabolite extraction efficiency, thereby improving the reproducibility of subsequent non-invasive profiling. The performance of the workflow was evaluated through the systematic assessment of instrumental stability and injection precision using pooled quality control (QC) samples. Following peak picking and alignment, a comprehensive raw dataset of 15,344 metabolic signals was generated, leading to the putative identification of 854 compounds. Unsupervised principal component analysis (PCA) demonstrated reproducible instrumental performance, indicated by tight QC sample clustering. From the total clinical cohort of 107 patients, a demographically matched sub-cohort of 50 individuals was evaluated to suppress confounding physiological noise. This comparative model revealed distinct disease-specific clustering and demonstrated significant perturbations in the tryptophan metabolic axis, membrane lipid remodeling, and enhanced proteolytic activity, characterized by an evident peptide overflow, associated with BCa progression. This systematically optimized methodology provides a reliable analytical approach for identifying non-invasive diagnostic panels, supporting the implementation of efficient laboratory workflows aligned with Analytics 5.0 principles.
Indexed as
Identifiers
42496706What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.